Combination of cancer vaccine and T cell therapy benefits patients with advanced ovarian cancer

A study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development can benefit patients with late-stage, drug-resistant ovarian cancer.